ATE310088T1 - Behandlung und nachweis von staphylokokkeninfektionen - Google Patents

Behandlung und nachweis von staphylokokkeninfektionen

Info

Publication number
ATE310088T1
ATE310088T1 AT99913444T AT99913444T ATE310088T1 AT E310088 T1 ATE310088 T1 AT E310088T1 AT 99913444 T AT99913444 T AT 99913444T AT 99913444 T AT99913444 T AT 99913444T AT E310088 T1 ATE310088 T1 AT E310088T1
Authority
AT
Austria
Prior art keywords
treatment
detection
staphylococcal infections
same
staphylococcal
Prior art date
Application number
AT99913444T
Other languages
English (en)
Inventor
James Peter Burnie
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Application granted granted Critical
Publication of ATE310088T1 publication Critical patent/ATE310088T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT99913444T 1998-03-31 1999-03-25 Behandlung und nachweis von staphylokokkeninfektionen ATE310088T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9806762.2A GB9806762D0 (en) 1998-03-31 1998-03-31 Treatment and diagnosis of staphylococcal infections
PCT/GB1999/000939 WO1999050418A1 (en) 1998-03-31 1999-03-25 Treatment and diagnosis of staphylococcal infections

Publications (1)

Publication Number Publication Date
ATE310088T1 true ATE310088T1 (de) 2005-12-15

Family

ID=10829514

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99913444T ATE310088T1 (de) 1998-03-31 1999-03-25 Behandlung und nachweis von staphylokokkeninfektionen

Country Status (12)

Country Link
US (1) US6627730B1 (de)
EP (1) EP1068328B1 (de)
JP (1) JP4460156B2 (de)
AT (1) ATE310088T1 (de)
AU (1) AU752794B2 (de)
CA (1) CA2321960A1 (de)
DE (1) DE69928384T2 (de)
DK (1) DK1068328T3 (de)
ES (1) ES2248992T3 (de)
GB (1) GB9806762D0 (de)
NZ (1) NZ506196A (de)
WO (1) WO1999050418A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
EP1412379B1 (de) 2001-08-02 2012-01-25 The University Of Sheffield Impfstoff
GB0127983D0 (en) 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
ES2730275T3 (es) 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
GB0515550D0 (en) 2005-07-29 2005-09-07 Univ Strathclyde Inactivation of staphylococcus species
US20080241127A1 (en) * 2006-12-29 2008-10-02 Dyax Corp. Methods of Making Passive Immunotherapies
WO2010129779A1 (en) * 2009-05-07 2010-11-11 Biomerieux, Inc. Methods for antimicrobial resistance determination
US9556281B2 (en) 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
US10918747B2 (en) 2015-07-30 2021-02-16 Vital Vio, Inc. Disinfecting lighting device
US10357582B1 (en) 2015-07-30 2019-07-23 Vital Vio, Inc. Disinfecting lighting device
CA2993825C (en) 2015-07-30 2020-08-25 Vital Vio, Inc. Single diode disinfection
US20180185533A1 (en) 2016-12-29 2018-07-05 Vital Vio, Inc. Control systems for disinfecting light systems and methods of regulating operations of disinfecting light systems
US10835627B2 (en) 2017-12-01 2020-11-17 Vital Vio, Inc. Devices using flexible light emitting layer for creating disinfecting illuminated surface, and related method
US10309614B1 (en) 2017-12-05 2019-06-04 Vital Vivo, Inc. Light directing element
US10413626B1 (en) 2018-03-29 2019-09-17 Vital Vio, Inc. Multiple light emitter for inactivating microorganisms
US12194168B2 (en) 2018-12-19 2025-01-14 Vyv, Inc. Lighting and dissipation device
US11639897B2 (en) 2019-03-29 2023-05-02 Vyv, Inc. Contamination load sensing device
US11541135B2 (en) 2019-06-28 2023-01-03 Vyv, Inc. Multiple band visible light disinfection
WO2021030748A1 (en) 2019-08-15 2021-02-18 Vital Vio, Inc. Devices configured to disinfect interiors
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
US11878084B2 (en) 2019-09-20 2024-01-23 Vyv, Inc. Disinfecting light emitting subcomponent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
GB9614274D0 (en) * 1996-07-06 1996-09-04 Univ Manchester Treatment and diagnosis of infections of gram positive cocci
ID21487A (id) * 1996-11-13 1999-06-17 Du Pont Metoda pembuatan 1,3 - propandiol dengan organisme rekombinan
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6300094B1 (en) * 1997-12-18 2001-10-09 Smithkline Beecham Corporation Polynucleotides encoding a novel ABC transporter

Also Published As

Publication number Publication date
WO1999050418A1 (en) 1999-10-07
AU752794B2 (en) 2002-10-03
JP2002509724A (ja) 2002-04-02
DE69928384D1 (de) 2005-12-22
CA2321960A1 (en) 1999-10-07
AU3156699A (en) 1999-10-18
DK1068328T3 (da) 2005-12-12
EP1068328A1 (de) 2001-01-17
DE69928384T2 (de) 2006-06-01
ES2248992T3 (es) 2006-03-16
US6627730B1 (en) 2003-09-30
NZ506196A (en) 2002-02-01
GB9806762D0 (en) 1998-05-27
JP4460156B2 (ja) 2010-05-12
EP1068328B1 (de) 2005-11-16

Similar Documents

Publication Publication Date Title
DE69928384D1 (de) Behandlung und nachweis von staphylokokkeninfektionen
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
DK0986577T3 (da) Opsonisk og beskyttende monoklonale og kimære antistoffer specifikke for lipoteichoicsyre af grampositive bakterier
BR0011838A (pt) Elementos misturadores estáticos empilhados
DE69433406D1 (de) Antikörper gegen cd40
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
ATE280160T1 (de) Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
ATE247973T1 (de) Verfahren zur kontrolle von antibiotikaresistenten grampositiven bakterien und behandlung von infektionen
GB0008305D0 (en) Treatment of fungal infections
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DE69838214D1 (de) Zubereitungen von mehreren antichlamydialen mitteln zur diagnose und behandlung von durch chlamydia verursachten infektionen
DE60125232D1 (de) Kleines säurelösliches sporenprotein und seine verwendungen
PT1095059E (pt) Proteina inibidora de quimiotaxia de estafilococos (chips) e sua utilizacao
BR7902303Y1 (pt) tambor para tratamento de couros, peles e similares.
DE69935662D1 (de) Mittel zur prävention/behandlung entzündlicher darmerkrankungen
DE69716056D1 (de) Acylurea-verbindungen zur behandlung von coccidioidomycosis bei warmblütigen tieren
ATE285796T1 (de) Präparation von hypericin gebunden an poly-n- vinylamiden
DE69601154D1 (de) Zubereitungen für die Behandlung von Hepatitis C
DE69524242D1 (de) Breit-reaktive opsonische antikörper, die mit gemeinsamen staphylococcus-antigenen reagieren
PT998493E (pt) Epitopos de toxina semelhante a shigella e a sua utilizacao como vacinas e em diagnosticos
EP1334131A4 (de) Monoklonale antikörper gegen das map-protein und verfahren zu dessen anwendung bei der behandlung bzw. prävention von infektionen
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
EA200001065A1 (ru) Применение фосфорорганических соединений для терапевтического и профилактического лечения инфекций

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1068328

Country of ref document: EP